Enfuvirtide(en foo veer’ tide)
Fuzeon
PREGNANCY CATEGORY B
Drug Classes
Anti-HIV drug
Fusion inhibitor
Therapeutic Actions
Prevents the entry of the HIV-1 virus into cells by inhibiting the fusion of the virus membrane with the viral and cellular membrane.
Indications
In combination with other antiretrovirals for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy
Contraindications and Cautions
Contraindicated with hypersensitivity to any component of enfuvirtide, lactation.
Use cautiously with history of lung disease, pregnancy.
Available Forms
Powder for injection—90 mg/mL
Dosages
Adults
90 mg bid by subcutaneous injection into the upper arm, anterior thigh, or abdomen.
Pediatric patients 6–16 yr
2 mg/kg bid by subcutaneous injection, up to a maximum of 90 mg/dose into the upper arm, anterior thigh, or abdomen.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
